ABSTRACT
Background & Aims Continued limitations in hepatocellular carcinoma (HCC) screening have led to late diagnosis with poor survival, despite well-defined high-risk patient populations. Our aim is to develop a non-invasive urine circulating tumor DNA (ctDNA) biomarker panel for HCC screening to aid in early detection.
Methods Candidate ctDNA biomarkers was prescreened in urine samples obtained from HCC, cirrhosis, and hepatitis patients. Then, 609 patient urine samples with HCC, cirrhosis, or chronic hepatitis B were collected from five academic medical centers and evaluated by serum alpha feto-protein (AFP) and urine ctDNA panel using logistic regression, a Two-Step machine learning algorithm, and iterated 10-fold cross-validation.
Results Mutated TP53, and methylated RASSF1a and GSTP1, were selected for the urine ctDNA panel. The sensitivity of AFP-alone (9.8 ng/mL cut-off) to detect HCC was 71% by Two-Step. The combination of ctDNA and AFP increased the sensitivity to 81% at a specificity of 90%. The AUROC for the combination of ctDNA and AFP vs. AFP-alone were 0.925 (95% CI, 0.924-0.925) and 0.877 (95% CI, 0.876-0.877), respectively. Notably, among the patients with AFP <20 ng/mL, the combination panel correctly identified 64% of HCC cases. The panel performed superiorly to AFP-alone in early-stage HCC (BCLC A) with 80% sensitivity and 90% specificity. In an iterated 10-fold cross-validation analysis, the AUROC for the combination panel was 0.898 (95% CI, 0.895-0.901).
Conclusions The combination of urine ctDNA and serum AFP can increase HCC detection rates including in those patients with low-AFP. Given the ease of collection, a urine ctDNA panel could be a potential non-invasive HCC screening test.
Competing Interest Statement
Disclosures: AK is a consultant to AstraZeneca, WS, SJ, SL are Shareholder of JBS Science Inc.
Funding Statement
This work is supported by R43CA165312, R44CA165312, R01CA202769, and K08CA237624.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was performed in compliance and after approval from the respective institutional review boards of all sites. Each participant signed a consent form for participation into the study, prior to data, blood, and urine collection.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Grant Support This work is supported by R43CA165312, R44CA165312, R01CA202769, and K08CA237624.
Disclosures AK is a consultant to AstraZeneca, WS, SJ, SL are Shareholder of JBS Science Inc.
Data Availability
The data generated and analyzed during this study are available from the corresponding author on reasonable request.
Abbreviations
- (AFP)
- alpha feto-protein
- (AUROC)
- area under the ROC
- (BCLC)
- Barcelona Clinic Liver Cancer staging system
- (BS)
- Bisulfite
- (ctDNA)
- circulating tumor DNA
- (CTNNB1 32-37)
- CTNNB1 codons 32-37
- (HCC)
- hepatocellular carcinoma
- (LR)
- logistic regression
- (LMW)
- low molecular weight
- (mGSTP1)
- methylated GSTP1
- (mRASSF1A)
- methylated RASSF1A
- (RF)
- random forest
- (ROC)
- Receiver operating characteristics
- (TP53 249)
- TP53 codon 249
- (TS)
- Two-Step
- (US)
- ultrasound